Tiziana Life Sciences (TLSA) News
NASDAQ: TLSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TLSA news summary
We found 9 recent headlines mentioning Tiziana Life Sciences (TLSA): 0 in the past week and 8 in the past 30 days, most often from Nasdaq, GlobeNewswire. TLSA is making an outsized move today, down 8.14% at $0.6206, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Tiziana Life Sciences Ltd to Present at the Jefferies Global Healthcare Conference 2026", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Tiziana Life Sciences headlines
- Tiziana Life Sciences Ltd to Present at the Jefferies Global Healthcare Conference 2026Tiziana Life Sciences Ltd announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London taking place from November 16-19, 2026. The presentation…Nasdaq
- Tiziana Life Sciences Ltd Highlights Positive Phase 2a INFORM-MS Topline Results and 12-Week Clinical Benefits of Intranasal ForalumabTiziana Life Sciences Ltd announced additional context on the positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in patients with non-active secondary progressive…Nasdaq
- Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal ForalumabBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…GlobeNewswire
- Tiziana Life Sciences Ltd to Present at BIO-Europe 2026 and Host KOL WebcastTiziana Life Sciences Ltd announced that it will present at BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Ivor Elrifi, Chief Executive Officer of Tiziana…Nasdaq
- Tiziana Life Sciences Ltd Announces Positive Phase 2a INFORM-MS Topline ResultsTiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development…Nasdaq
- Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline ResultsBOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…GlobeNewswire
- Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis Trial(RTTNews) - Tiziana Life Sciences (TLSA) reported positive topline results from its Phase 2a INFORM-MS study, showing that intranasal foralumab met both primary endpoints in patients with non-active…NasdaqTLSA, BF.A
- Tiziana Eyes Next Foralumab Milestones After Positive Progressive MS Data; Stock Down(RTTNews) - Tiziana Life Sciences Ltd. (TLSA), a clinical-stage biotechnology company, on Monday announced positive topline results from its Phase 2a INFORM-MS trial evaluating intranasal foralumab…NasdaqTLSA, WSO.B
- Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s DiseaseBOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…GlobeNewswire